Dr. Xian Pan is a Principal Scientist at Certara Predictive Technologies. She received her BSc in Pharmacy and an MSc in Pharmacokinetics from China Pharmaceutical University and earned a Ph.D. in Biopharmaceutical Sciences from the University of Illinois at Chicago. Her doctoral work focused on understanding the altered pharmacokinetics during pregnancy, specifically investigating the molecular mechanisms of CYP2D6 induction and interindividual variabilities. She has worked in the industry as a Senior Research Scientist, leading and managing preclinical DMPK projects from drug discovery to IND filing. Since joined Certara Predictive Technologies in 2017, she has significantly contributed to PBPK framework enhancement, including various modules’ development and expansion for small molecule drugs and therapeutic proteins, and evaluation of drug-drug interaction liabilities for both modalities. She has actively contributed to the expansion of the virtual populations for pediatrics, premature neonates, and fetus. She has several publications in the field and provided training and consultancy for a number of pharmaceutical companies.